Literature DB >> 12212978

Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens.

O Leroy1, P Giradie, Y Yazdanpanah, H Georges, S Alfandari, V Sanders, P Devos, G Beaucaire.   

Abstract

Adequate antimicrobial therapy is a main approach employed to decrease the mortality associated with hospital-acquired pneumonia (HAP). All methods that optimise empirical treatment without increasing antibiotic selective pressure are relevant. Categorisation of patients according to HAP time of onset, severity and risk factors (American Thoracic Society (ATS) classification) or duration of mechanical ventilation and prior antibiotics (Trouillet's classification) are two such methods. The aim of this study was to catagorise patients with HAP according to these classifications and to determine the frequency of resistant pathogens and the most adequate antimicrobial regimens in each group. A total 124 patients with bacteriologically proven HAP were studied. The ATS classification categorised patients by increasing frequency of resistant pathogens from 0-30.3%. The ATS empirical antibiotic recommendations appeared valid but proposed combinations including vancomycin for 72.5% of patients. Trouillet's classification categorised patients into four groups with a frequency of resistant pathogens from 4.9-35.6%. Vancomycin was proposed for 48.5% of patients. The American Thoracic Society classification appears to be more specific than Trouillet's for predicting the absence of resistant causative pathogens in hospital-acquired pneumonia but could lead to a greater use of vancomycin. Stratification combining the two classifications is an interesting alternative.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212978     DOI: 10.1183/09031936.02.00267602

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

1.  M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections.

Authors:  Stefan Hagel; Svenja Schmitt; Miriam Kesselmeier; Michael Baier; Tobias Welte; Santiago Ewig; Mathias W Pletz
Journal:  Infection       Date:  2019-01-28       Impact factor: 3.553

2.  Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome.

Authors:  David Orlikowski; Tarek Sharshar; Raphael Porcher; Djillali Annane; Jean Claude Raphael; Bernard Clair
Journal:  Intensive Care Med       Date:  2006-09-21       Impact factor: 17.440

3.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

4.  Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia.

Authors:  P Depuydt; D Benoit; D Vogelaers; J Decruyenaere; D Vandijck; G Claeys; G Verschraegen; S Blot
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

5.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.